Experimental women's cancer drug boosts survival rates in notable study
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company
Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...
Zacks Investment Research on MSN1d
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of ...
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...
Corcept Therapeutics announces ROSELLA trial meets primary endpoint
Corcept Therapeutics (CORT) announced that Rosella, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with ...
Zacks.com on MSN2d
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast
Corcept's ROSELLA trial met its primary endpoint, showing relacorilant improved progression-free and overall survival in ...
Fierce Biotech3d
Corcept's investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...
CURE3d
Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...
Zacks Investment Research on MSN2d
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
Corcept Therapeutics (CORT) shares rallied 109.1% in the last trading session to close at $114.22. This move can be attributable to notable volume with a higher number of shares being traded than in a ...